As teamLab Planets in Tokyo Welcomes Around 1 Million Visitors From Abroad in a 6-Month Period, the Immersive Museum Unveils the Renewal of Artwork Spaces
teamLab Planets TOKYO DMM ("teamLab Planets"), the body-immersive museum by art collective teamLab in Toyosu, Tokyo, celebrated its fifth anniversary with the renewal of artwork spaces, making it an even more immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830716639/en/
As visitors touch the countless crystals of light floating in the air, the work transforms interactively. On view at teamLab Planets, a body immersive museum in Toyosu, Tokyo. (teamLab, Ephemeral Solidified Light / Photo: teamLab)
In the six months from March to August 2023, the museum has received approximately one million visitors from 182 countries and regions outside of Japan. This makes up 70% of the museum’s total number of visitors (*1). It has also been reported that approximately 1 in 10 visitors to Japan from overseas are visiting teamLab Planets (*2).
NEWLY UNVEILED INSTALLATION: EPHEMERAL SOLIDIFIED LIGHT
Inside an immersive artwork that visitors experience by entering the water, countless masses of light float in the air, each one composed of multiple colors. The boundaries of each color are clearly separated as though they are solid. The seemingly solid color separation of the masses of light is not seen in the natural world, and is caused by extreme synchronization. Through self-organization over time, this synchronization phenomenon creates a large ordered structure.
RENEWAL OF ARTWORK SPACES
In The Infinite Crystal Universe, an artwork that creates a three-dimensional sculpture from a collection of light points, visitors can participate in the work using the teamLab app and create the artwork together with other people in the space. By throwing in a star of your choice from the app, a light sculpture is created in front of you, and the space of this work is created by a group of these light sculptures. With the renewal, five new light sculptures have been added to the installation.
An installation filled with spheres of light that change to ambiguous colors through people’s interactions, Expanding Three-dimensional Existence in Transforming Space, and several other artwork spaces have also been renewed, furthering the experience of physically immersing the entire body.
In addition, teamLab Planets, which was originally scheduled to close at the end of 2023, has been extended to the end of 2027 due to the popularity of the museum.
CONCEPT BEHIND TEAMLAB PLANETS
Together with Others, Immerse your Entire Body, Perceive with your Body, and Become One with the World
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
People go barefoot and immerse their entire bodies in the vast artworks together with others. The artworks change under the presence of people, blurring the perception of boundaries between the self and the works. Other people also create change in the artworks, blurring the boundaries between themselves and the works, and creating a continuity between the self, the art, and others.
-----------------------
*1, teamLab Planets Official Website, Ticket Purchasing Data (data obtained from March 1st - Aug 31st, 2023)
*2 “Amazing Nippon / Digital Art Museum in Tokyo Enchants Overseas Tourists - The Japan News” The Japan News by the Yomiuri Shimbun. August 5, 2023.
About the Museum
teamLab Planets TOKYO DMM
6-1-16 Toyosu, Koto-ku, Tokyo
https://www.teamlab.art/e/planets/
Hours
September - November: 09:00 - 22:00
*Last entry 1 hour before closing
*Hours are subject to change. Please check the official website for the latest information.
Closed: September 6th (Wed), October 4th (Wed), November 8th (Wed)
Admission
Adult (18 years and over): 3,800 JPY
Student (13 - 17 years): 2,300 JPY
Child (4 - 12 years): 1,300 JPY
3 years and under: Free
Disability discount: 1,900 JPY
Official Ticket Store
https://teamlabplanets.dmm.com
Food & Shop
Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo-en
teamLab Flower Shop: https://www.teamlab.art/e/flowershop/
For Media
Press Kit: https://goo.gl/tQXMLm
Highlight Video: https://youtu.be/KAQMAzRjoH0
About PLANETS Co., Ltd.
Established in 2017. Operates and manages the facilities of teamLab Planets TOKYO.
Location: Tokyo Nihonbashi Tower 10F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto
About teamLab
teamLab (f. 2001) is an international art collective. Their collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world. Through art, the interdisciplinary group of specialists, including artists, programmers, engineers, CG animators, mathematicians, and architects, aims to explore the relationship between the self and the world, and new forms of perception.
In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perceptions of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab exhibitions have been held in cities worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, and Melbourne among others. teamLab museums and large-scale permanent exhibitions include teamLab Borderless and teamLab Planets in Tokyo, teamLab Borderless Shanghai, teamLab SuperNature Macao, and teamLab Massless Beijing, with more to open in cities including Abu Dhabi, Hamburg, Jeddah, and Utrecht.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki, among others.
teamLab is represented by Pace Gallery, Martin Browne Contemporary, and Ikkan Art.
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830716639/en/
Contact information
PLANETS Co., Ltd. Public Relations Department
E-mail: pr-info@planets.art
Interview: https://forms.gle/fAtnDKLpQKFME6XR9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom